Conduit Pharmaceuticals Inc. (CDT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) has a cash flow conversion efficiency ratio of 0.194x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($245.00 Million) by net assets ($1.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Conduit Pharmaceuticals Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CDT current and long-term liabilities for a breakdown of total debt and financial obligations.
Conduit Pharmaceuticals Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Conduit Pharmaceuticals Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kmi Wire And Cable Tbk
JK:KBLI
|
-0.009x |
|
Portage Biotech Inc
NASDAQ:PRTG
|
-2.245x |
|
Wave Entertainment Public Company Limited
BK:WAVE
|
-0.011x |
|
Adavale Resources Ltd
AU:ADD
|
19.781x |
|
Artemis Resources Ltd
AU:ARV
|
-0.059x |
|
Finsbury Growth & Income Trust
LSE:FGT
|
0.013x |
|
Inotiv Inc
NASDAQ:NOTV
|
-0.050x |
|
SL Private Equity
LSE:SLPE
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Conduit Pharmaceuticals Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see CDT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.26 Billion | $354.86 Million | 0.281x | -80.31% |
| 2024-12-31 | $-6.79 Million | $-9.68 Million | 1.425x | -91.57% |
| 2023-12-31 | $-457.00K | $-7.72 Million | 16.904x | +7426.11% |
| 2022-12-31 | $-10.09 Million | $-2.27 Million | 0.225x | +100.22% |
| 2021-12-31 | $20.62K | $-2.15 Million | -104.321x | -- |
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, whic… Read more